BYETTA
Generic Name for BYETTA
Exenatide 250micrograms/mL; soln for SC inj; contains m-cresol and mannitol.
Legal Classification:
Rx
Pharmacological Class for BYETTA
Incretin mimetic.
Manufacturer of BYETTA
Amylin and Lilly
|
Indications for BYETTA
Adjunct to diet and excercise to improve glycemic control in adults with type 2 diabetes.
Adult dose for BYETTA
Give by SC inj into thigh, abdomen, or upper arm within 60 minutes before AM and PM meals. Initially 5micrograms twice daily; may increase to 10micrograms twice daily after 1 month. Moderate renal impairment (CrCl 30–50mL/min): caution when initiating or escalating doses from 5mcg to 10mcg.
Children's dosing for BYETTA
Not recommended.
Contraindications for BYETTA
Type 1 diabetes. Not for treatment of diabetic ketoacidosis. Postprandial administration.
Warnings/Precautions for BYETTA
Not a substitute for insulin. History of pancreatitis; consider other antidiabetic therapies. Monitor for pancreatitis; if suspected, promptly discontinue; if confirmed, do not restart. Severe GI disorders, renal impairment (CrCl <30mL/min), end-stage renal disease: not recommended. Renal transplantation. Pregnancy (Cat.C). Nursing mothers.
Interactions for BYETTA
Consider reducing concomitant sulfonylurea dose. Concurrent insulin, D-phenylalanine derivatives, meglitinides, α-glucosidase inhibitors: not recommended. Hypoglycemia possible with sulfonylurea. May delay absorption of oral drugs (take these 1 hour before exenatide). Monitor warfarin.
Adverse Reactions for BYETTA
GI upset, hypoglycemia, dizziness, headache, asthenia, reduced appetite, weight loss, GERD, hyperhidrosis; antibody formation (glycemic response may be attenuated), pancreatitis (may be fatal).
How is BYETTA supplied?
Prefilled pen (needles not included): 5micrograms/dose—1 (60 doses)
10micrograms/dose—1 (60 doses)
Related Disease:
Diabetes mellitus~hyperglycemic agents